Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.
Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.
CURIS, INC.: Nantahala Capital Partners LP reported beneficial ownership of 2,944,000 shares of Common Stock as of March 31, 2026. This holding represents 6.98% of the class, based on 39,978,693 shares outstanding as of March 27, 2026. The reported total includes 2,208,000 shares exercisable within sixty days.
Curis Inc. director Kenneth I. Kaitin reported an open-market purchase of 10,000 shares of Curis common stock at $0.5487 per share. After this transaction, his direct ownership increased to 11,407 shares, indicating a meaningful addition relative to his prior holdings.
CURIS INC filed a Schedule 13G reporting a shared beneficial ownership position of 4,025,992 shares, equal to 9.9% of the outstanding common stock. The reporting persons are Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico, filing jointly.
The filing states the calculation is based on 39,978,693 shares outstanding as of March 20, 2026. It also discloses warrants to acquire 10,000,002 shares that are subject to a 9.99% beneficial ownership limitation. Voting and dispositive power are reported as shared for the 4,025,992 shares; sole voting/dispositive power is reported as 0 for each reporting person.
Curis, Inc. is a biotechnology company focused almost entirely on developing emavusertib (CA-4948), an oral IRAK4/FLT3 inhibitor for hematologic cancers including PCNSL, CLL and AML. Emavusertib has Orphan Drug Designation in the U.S. for PCNSL, AML and MDS, and in Europe for PCNSL.
The company highlights substantial financial strain. As of December 31, 2025, it held $5.1 million in cash and cash equivalents and subsequently raised about $18.6 million net in a January 2026 PIPE financing. Management states there is substantial doubt about Curis’s ability to continue as a going concern and that significant additional capital will be required to fund development and operations.
Curis may need equity financings, collaborations or strategic alternatives, including asset sales or a sale of the company, and acknowledges potential outcomes such as dissolution or bankruptcy if funding cannot be secured. In November 2025, it sold its Erivedge royalty entity, ending revenue from the Genentech collaboration. As of March 20, 2026, there were 39,978,693 common shares outstanding, and Curis also notes the risk of Nasdaq delisting if listing standards are not maintained.
CURIS INC CDO Jonathan B. Zung converted preferred stock into common shares. On March 20, 2026, he converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock for no additional cash consideration. Following the conversion, he holds 66,667 common shares directly.
Curis Inc. Chief Medical Officer Ahmed Hamdy converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock were converted into 66,667 shares of common stock for no additional consideration, leaving no Series B Preferred outstanding for him and 66,667 common shares held directly.
CURIS INC CFO Diantha Duvall converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock automatically converted into 66,666 shares of Common Stock for no additional consideration, increasing her direct common stock holdings to 77,707 shares.
Each share of Series B Preferred Stock converts into 1,333.33 common shares under the company’s Certificate of Designations and is subject to specified beneficial ownership limitations. This filing reflects an internal capital structure change for the executive rather than an open‑market purchase or sale.
Curis Inc. reported that President & CEO James E. Dentzer converted preferred shares into common stock. On March 20, 2026, he converted 100 shares of Series B Convertible Non-Redeemable Preferred Stock into 133,333 shares of common stock for no additional consideration through an automatic conversion.
After the conversion, Dentzer directly owned 148,730 shares of Curis common stock. Each Series B preferred share converted into 1,333.33 common shares, consistent with the terms described in the related certificate of designations and subject to specified beneficial ownership limitations.
Curis Inc director Marc Rubin converted preferred stock into common shares. On March 20, 2026, he converted 20 shares of Series B Convertible Preferred Stock into 26,667 shares of Common Stock for no additional consideration through an automatic conversion.
Following the conversion, Rubin directly owned 28,108 shares of Curis Common Stock. The preferred shares were originally sold as part of a $1,000.00 "Security" unit that also included Series A, B and C warrants, and converted subject to stated beneficial ownership limitations.